PRECLINICAL & TRANSLATIONAL EXPERTISE
Preclinical & Translational Expertise
De-Risking Early Development. Enabling Clinical Success.
The transition from discovery to clinical development is one of the most critical—and failure-prone—stages in drug development. Scientific uncertainty, inadequate study design, and poor translational alignment can lead to regulatory delays, failed IND submissions, or unsuccessful clinical trials.
Our advisory platform provides integrated preclinical and translational expertise to ensure that programs are scientifically robust, regulator-ready, and positioned for clinical success.
Our Approach
From Biology to First-in-Human Readiness
We align biology, safety, pharmacology, and regulatory strategy into a cohesive development plan that supports efficient progression to the clinic.
Our approach focuses on:
- Building a defensible scientific foundation
- Designing regulatory-aligned preclinical programs
- Translating preclinical findings into clinical strategy
- Identifying and mitigating early-stage risks
Core Capabilities
1. Target Biology & Mechanism of Action
What We Do
- Evaluate target biology and disease relevance
- Assess mechanism of action (MoA) and therapeutic rationale
- Analyze competitive landscape and differentiation
- Identify potential off-target effects and risks
Value
- Ensures scientific credibility of the program
- Differentiates assets in competitive therapeutic areas
- Reduces risk of late-stage failure due to weak biology
2. Preclinical Development Strategy
What We Do
- Design integrated preclinical development plans
- Define IND-enabling study strategy
- Align timelines with clinical and regulatory milestones
- Select appropriate animal models and endpoints
Value
- Creates a clear, executable roadmap to IND
- Avoids redundant or misaligned studies
- Optimizes cost and development timelines
3. Toxicology & Safety Assessment
What We Do
- Design GLP toxicology programs
- Develop safety pharmacology strategies
- Identify dose-limiting toxicities and safety margins
- Support risk mitigation strategies
Value
- Reduces likelihood of IND delays or clinical holds
- Strengthens regulatory confidence
- Enables safe and effective dose selection
4. Pharmacokinetics / Pharmacodynamics (PK/PD)
What We Do
- Characterize drug exposure and disposition
- Develop PK/PD models linking exposure to efficacy
- Support dose selection and escalation strategies
- Evaluate drug-drug interaction potential
Value
- Enables rational dosing strategies
- Improves clinical trial design
- Increases probability of clinical success
5. Translational Medicine & Biomarkers
What We Do
- Develop translational strategies bridging preclinical to clinical
- Identify and validate biomarkers
- Align preclinical endpoints with clinical outcomes
- Support precision medicine approaches
Value
- Improves predictability of clinical outcomes
- Enables data-driven decision-making
- Strengthens clinical development strategy
6. IND-Enabling Programs
What We Do
- Design and integrate all IND-enabling studies
- Ensure regulatory compliance and documentation readiness
- Support preparation of IND submissions
- Prepare for regulatory interactions
Value
- Accelerates IND readiness
- Reduces risk of regulatory deficiencies
- Enables smooth transition to clinical development
7. Early Clinical Translation (Phase I Readiness)
What We Do
- First-in-human (FIH) study design
- SAD/MAD protocol development
- Starting dose justification
- Exposure-response strategy
Value
- Ensures safe and efficient entry into clinical trials
- Aligns preclinical data with clinical execution
- Reduces early clinical risk
Integrated Expertise Across Modalities
- Small molecules
- Biologics (monoclonal antibodies, proteins)
- Cell and gene therapies
- Vaccines
- Diagnostics and companion diagnostics
Common Challenges We Solve
We are frequently engaged to address:
- Weak or unclear translational strategy
- Gaps in IND-enabling data packages
- Misaligned toxicology or PK/PD programs
- Uncertain dose selection strategies
- Regulatory concerns prior to IND submission
- Programs at risk of delay or failure
Value to Clients
Reduce Development Risk
Identify scientific and safety risks early—before costly clinical failure.
Accelerate Timelines
Design efficient, regulator-aligned preclinical programs.
Strengthen Regulatory Positioning
Ensure IND packages meet expectations and withstand scrutiny.
Improve Clinical Success Probability
Translate preclinical insights into robust clinical strategies.
Who We Work With
- Biotech companies preparing for IND
- Pharmaceutical companies optimizing early development programs
- Venture capital and private equity firms conducting diligence
- Companies developing novel or complex therapeutic platforms
Why Our Approach Works
Operator-Led Expertise
Led by experts with decades of experience in toxicology, clinical pharmacology, and translational science.
Integrated Thinking
We connect preclinical science with clinical, regulatory, and manufacturing realities.
Regulatory Alignment
Our strategies are built with regulatory expectations in mind from the start.
Practical Execution
We deliver actionable recommendations—not theoretical analysis.
Bottom Line
We transform early-stage science into clinically actionable, regulator-ready programs—reducing risk, accelerating timelines, and improving the likelihood of success in human trials.
Number of companies: 3
Number of contacts: 4
Back to Home
